Phase II trial of Tarceva [erlotinib] following concurrent chemo-radiotherapy as first line therapy in patients with unresectable non-small cell lung cancer

Trial Profile

Phase II trial of Tarceva [erlotinib] following concurrent chemo-radiotherapy as first line therapy in patients with unresectable non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2014 Primary endpoint of progression-free rate has been met, according to results published in the Cancer Chemotherapy and Pharmacology.
    • 01 Mar 2014 Status changed from recruiting to completed according to results published in the Cancer Chemotherapy and Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top